Radiation with hormone therapy timing for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your prostate cancer has come back after initial treatment and is now in a few spots (5 or fewer) outside the pelvis, but you have not had chemotherapy for it.
- Your testosterone levels should be normal (higher than 100 ng/dL) — meaning you have not yet been on long-term hormone therapy.
- You must be in fairly good health (able to care for yourself, up and about at least 50% of the time).
- You have not taken certain strong hormone therapy drugs (like abiraterone, enzalutamide, apalutamide, or darolutamide) in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.